Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Innoviva (INVA) stock in plain English

Free brief · no signupStart here
INVAPublished Nov 16, 2026
Innoviva Inc
Healthcare · Biotechnology
Collects recurring royalties from GlaxoSmithKline on global respiratory inhaler sales. Sells proprietary antibiotic and cardiovascular treatments directly to hospitals and health systems.
Assets:
GSK Royalty StreamCovers Trelegy, Relvar/Breo, and Anoro Ellipta sales
Xacduro TreatmentTargeted hospital antibiotic for resistant bacterial pneumonia
Critical Care LineupIncludes hospital drugs Giapreza and Xerava
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

80
OPS ScoreOperating finances
Latest quote
+0.05%$18.41
$1.31B
9.2×
$452.81M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 16, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was INVA. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Innoviva (INVA) do?

Innoviva Inc (INVA) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Collects recurring royalties from GlaxoSmithKline on global respiratory inhaler sales. Sells proprietary antibiotic and cardiovascular treatments directly to hospitals and health systems. Collects respiratory drug royalties from major pharmaceutical partners and sells critical-care hospital treatments. It is worth $1.31B on the market and sold $452.81M over the last year.

Market cap
$1.31B
P/E ratio
9.2×
Annual sales
$452.81M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 16, 2026

Brands and businesses behind INVA

  • Xacduro: Treats hospital-acquired bacterial pneumonia and earns revenue from direct sales to acute care medical centers.
  • Giapreza: Increases blood pressure in septic shock patients and earns revenue through hospital pharmaceutical orders.
  • Xerava: Treats complicated intra-abdominal bacterial infections in adults, earning revenue from inpatient medical sales.

INVA’s flags, in plain English

Each flag is a number from Innoviva’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.

Stupid Cash

Can pay this year's bills 15.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Fat Margins

Profit margin of 42.8%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Wide Gross Margin

Gross margin of 72.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Growth Cooling

Sales growth slowed to 3.9% a year over 5 years. Sales are growing more slowly than before, which makes the current share price harder to justify.

2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about INVA

How big is Innoviva?

Innoviva’s market cap is $1.31B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $452.81M: what customers paid the company over the last year, before any costs.

What is INVA’s P/E ratio?

INVA’s P/E ratio is 9.2×. Investors pay about 9.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with INVA?

A large portion of total cash flow depends on the commercial sales performance of partner GlaxoSmithKline. That is one risk on Innoviva’s card. Its first risk flag is Growth Cooling, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Innoviva’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. INVA’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card